Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. An immunohistochemical and morphometric study of sequential trephine biopsies

Haematologica

Volumn 88, Issue 10, 2003, Pages 1130-1138

  Thiele, Juergen ^a   Kvasnicka, Hans Michael ^a   Fuchs, Nina ^a   Brunnbauer, Kerstin ^a   Volkwein, Nina ^a   Schmitt Graeff, Annette ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE

Author keywords

Anagrelide; Angiogenesis; Apoptosis; Megakaryopoiesis; Proliferation

Indexed keywords

ANAGRELIDE; CELL NUCLEUS ANTIGEN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CELL COUNT; CELL MATURATION; CELL PROLIFERATION; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MORPHOMETRICS; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; POLYPLOIDY; STEM CELL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS; TREATMENT OUTCOME;

ADULT; AGED; BIOPSY; BLOOD PLATELETS; BONE MARROW; CHRONIC DISEASE; DRUG EVALUATION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PLATELET COUNT; QUINAZOLINES; RETROSPECTIVE STUDIES; THROMBOCYTOSIS;

EID: 0242299236     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Tang SS, Frojmovic MM. Inhibition of platelet function by antithrombotic agents which selectively inhibit low-Km cyclic 3′,5′-adenosine monophosphate phosphodiesterase. J Lab Clin Med 1980;95:241-57.
2. Abe Andes W, Noveck RJ, Fleming JS. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb Haemost 1984;52:325-8.
3. Mazur EM, Rosmarin AG, Sohl PA, Newton JL, Narendran A. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992;79:1931-7.
4. Spencer CM, Brogden RN. Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs 1994;47:809-22.
5. Oertel MD. Anagrelide, a selective thrombocytopenic agent. Am J Health Syst Pharm 1998;55:1979-86.
6. Ravandi-Kashani F, Schafer Al. Microvascular disturbances, thrombosis, and bleeding in thrombocythemia: current concepts and perspectives. Semin Thromb Hemost 1997;23: 479-88.
7. Silverstein MN, Petitt RM, Solberg LA Jr, Fleming JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988;318:1292-4.
8. Balduini CL, Bertolino G, Noris P, Ascari E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica 1992;77:40-3.
9. Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F, Mandelli F. Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Haematologica 1992;77:315-7.
10. Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Semin Thromb Hemost 1997;23:37983.
11. Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol 1998;61:71-6.
12. Bellucci S, Legrand C, Boval B, Drouet L, Caen J. Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with anagrelide. Br J Haematol 1999;104:886-92.
13. Silverstein MN, Tefferi A. Treatment of essential thrombocythemia with anagrelide. Semin Hematol 1999;36:23-5.
14. Laguna MS, Kornblihtt LI, Marta RF, Michiels JJ, Molinas FC. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin Appl Thromb Hemost 2000;6:157-61.
15. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992; 92:69-76.
16. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 1997;34:51-4.
17. Andersson BS. Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide. Hematology 2002;7:173-7.
18. Solberg LA Jr. Therapeutic options for essential thrombocythemia and polycythemia vera. Semin Oncol 2002;29:10-5.
19. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001; 97:863-6.
20. Liozon E, Brigaudeau C, Trimoreau F, Desangles F, Fermeaux V, Praloran V, et al. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. Hematol Cell Ther 1997;39:11-8.
21. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-22.
22. Finazzi G, Barbui T. Treatment of essential thrombocythemia with special emphasis on leukemogenic risk. Ann Hematol 1999;78:389-92.
23. Randi ML, Fabris F, Girolami A. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia. Leuk Lymphoma 2000;37:379-85.
24. Brooks WG, Stanley DD, Goode JV. Role of anagrelide in the treatment of thrombocytosis. Ann Pharmacother 1999; 33:1116-21.
25. Gilbert HS. Other secondary sequelae of treatments for myeloproliferative disorders. Semin Oncol 2002;29:22-7.
26. Solberg LA Jr, Tefferi A, Oles KJ, Tarach JS, Petitt RM, Forstrom LA, et al. The effects of anagrelide on human megakaryocytopoiesis. Br J Haematol 1997;99:174-80.
27. Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1999;106:682-8.
28. Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood 2002;99:1602-9.
29. Imbert M, Pierre R, Thiele J, Vardiman JW, Brunning RD, Flandrin G. Essential thrombocythaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press. 2001. p. 39-41.
30. Thiele J, Imbert M, Pierre R, Vardiman JW, Brunning RD, Flandrin G. Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press. 2001. p. 35-8.
31. Soligo D, Delia D, Oriani A, Cattoretti G, Orazi A, Bertolli V, et al. Identification of CD34+ cells in normal and pathological bone marrow biopsies by QBENDIO monoclonal antibody. Leukemia 1991;5:1026-30.
32. Gatter KC, Cordell JL, Turley H, Heryet A, Kieffer N, Anstee DJ, et al. The immunohistological detection of platelets, megakaryocytes and thrombi in routinely processed specimens. Histopathology 1988;13:257-67.
33. Hall PA, Levison DA. Review: assessment of cell proliferation in histological material. J Clin Pathol 1990;43:184-92.
34. McCormick D, Hall PA. The complexities of proliferating cell nuclear antigen. Histopathology 1992;21:591-4.
35. Thiele J, Meuter RB, Titius RB, Zankovich R, Fischer R. Proliferating cell nuclear antigen expression by erythroid precursors in normal bone marrow, in reactive lesions and in polycythaemia rubra vera. Histopathology 1993;22:429-35.
36. Bauermeister DE. Quantitation of bone marrow reticulin: a normal range. Am J Clin Pathol 1971;56:24-31.
37. Thiele J, Kvasnicka HM, Boeltken B, Zankovich R, Diehl V, Fischer R. Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) - a clinicopathological study. Leukemia 1999;13:1741-8.
38. Thiele J, Wagner S, Dienemann D, Wienhold S, Fischer R, Stein H. Megakaryocyte precursors (promegakaryoblasts and megakaryoblasts) in the normal human bone marrow. An immunohistochemical and morphometric study on routinely processed trephine biopsies. Anal Quant Cytol Histol 1990; 12:285-9.
39. Thiele J, Wagner S, Degel C, Dienemann D, Wienhold S, Zankovich R, et al. Megakaryocyte precursors (pro- and megakaryoblasts) in bone marrow tissue from patients with reactive thrombocytosis, polycythemia vera and primary (essential) thrombocythemia. An immunomorphometric study. Virchows Arch B Cell Pathol Incl Mol Pathol 1990;58: 295-302.
40. Vinci G, Tabilio A, Deschamps JF, Van Haeke D, Henri A, Guichard J, et al. Immunological study of in vitro maturation of human megakaryocytes. Br J Haematol 1984;56:589-605.
41. Breton-Gorius J, Vainchenker W. Expression of platelet proteins during the in vitro and in vivo differentiation of megakaryocytes and morphological aspects of their maturation. Semin Hematol 1986;23:43-67.
42. Ishibashi T, Ruggeri ZM, Harker LA, Burstein SA. Separation of human megakaryocytes by state of differentiation on continuous gradients of Percoll: size and ploidy analysis of cells identified by monoclonal antibody to glycoprotein IIb/IIIa. Blood 1986;67:1286-92.
43. Levene RB, Williams NT, Lamaziere JM, Rabellino EM. Human megakaryocytes. IV. Growth and characterization of clonable megakaryocyte progenitors in agar. Exp Hematol 1987; 15:181-9.
44. Levine RF, Hazzard KC, Lamberg JD. The significance of megakaryocyte size. Blood 1982;60:1122-31.
45. Williams N, Levine RF. The origin, development and regulation of megakaryocytes. Br J Haematol 1982;52:173-80.
46. Hoffman R. Regulation of megakaryocytopoiesis. Blood 1989;74:1196-212.
47. Tomer A, Friese P, Conklin R, Bales W, Archer L, Harker LA, et al. Flow cytometric analysis of megakaryocytes from patients with abnormal platelet counts. Blood 1989;74:594-601.
48. Queisser U, Queisser W, Spiertz B. Polyploidization of megakaryocytes in normal humans, in patients with idiopathic thrombocytopenia and with pernicious anaemia. Br J Haematol 1971;20:489-501.
49. Thiele J, Titius BR, Kvasnicka HM, Bertsch HP, Erdmann S, Fischer R. Proliferating cell nuclear antigen (PCNA) expression of megakaryocytopoiesis in normal human bone marrow and reactive lesions with special emphasis on HIV-myelopathy. Pathol Res Pract 1994;190:42-50.
50. Thiele J, Bertsch HP, Kracht LW, Anwander T, Zimmer JD, Kreipe H, et al. Ki-S1 and PCNA expression in erythroid precursors and megakaryocytes: a comparative study on proliferative and endoreduplicative activity in reactive and neoplastic bone marrow lesions. J Pathol 1994;173:5-12.
51. Le Bousse-Kerdiles MC, Martyre MC. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol 1999;78:437-44.
52. Lev PR, Marta RF, Vassallu P, Molinas FC. Variation of PDGF, TGFbeta, and bFGF levels in essential thrombocythemia patients treated with anagrelide. Am J Hematol 2002; 70:85-91.
53. Buhr T, Georgii A, Choritz H. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathol Res Pract 1993; 189:121-32.
54. Georgii A, Buesche G, Kreft A. The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol 1998; 11:721-49.
55. Buhr T, Busche G, Choritz H, Langer F, Kreipe H. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol 2003;119:152-8.
56. Thiele J, Kvasnicka HM, Schmitt-Gräff A, Diehl V. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. Leuk Lymphoma 2003;44:549-53.
57. James CW. Anagrelide-induced cardiomyopathy. Pharmacotherapy 2000;20:1224-7.
58. Pescatore SL, Lindley C. Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Expert Opin Pharmacother 2000;1:537-46.